Brief: Vbi Vaccines And Brii Biosciences Expand Hepatitis B Partnership
05/07/2023 21:24
July 5 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES AND BRII BIOSCIENCES EXPAND HEPATITIS B
PARTNERSHIP
TO ADDRESS BOTH PREVENTION AND TREATMENT IN LICENSE AND
COLLABORATION AGREEMENTS FOR UP TO $437 MILLION PLUS ROYALTIES
* VBI VACCINES - CO ELIGIBLE TO RECEIVE UP TO $422 MILLION
IN
ADDITIONAL POTENTIAL REGULATORY AND COMMERCIAL MILESTONE
PAYMENTS, PLUS DOUBLE-DIGIT ROYALTIES
* VBI VACCINES - BRII BIOSCIENCES HAS ACQUIRED WORLDWIDE
EXCLUSIVE
LICENSE TO VBI-2601 AND AN EXCLUSIVE LICENSE FOR PREHEVBRI® IN
ASIA PACIFIC REGION
Source text for Eikon: ID:nBw66KbmYa
Further company coverage: VBIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55